Subcutaneous golimumab to treat a biological na ïve chronically active ulcerative colitis child. A case report

CONCLUSION: This case demonstrated that golimumab 200 mg, 100 mg at week 0, 2 as an induction then 50 mg every four weeks was efficacious and safe in<45 kg children, there were no side effects or adverse events during two years therapy period.PMID:35386809 | PMC:PMC8977938 | DOI:10.1016/j.amsu.2022.103456

Source: Annals of Medicine - April 7, 2022 Category: Internal Medicine Authors: Marouf M Alhalabi Ahmad J Abbas Source Type: research